On July 10, Iluvatar CoreX (09903.HK) fell 5.65% in regular trading, trading at HK$575.5/share, with turnover of HK$348 million.

The decline was driven by the company's announcement on July 9 of a placement agreement with Goldman Sachs, Morgan Stanley, Huatai International, and J.P. Morgan to place 14.857 million new H shares at HK$476 per share, representing approximately a 15% discount to the prior closing price of HK$560 and roughly a 19.4% discount to the five-day average. The placement is expected to raise net proceeds of approximately HK$7.034 billion, with the new shares representing about 5.84% of total issued share capital.

The fundraising, initiated merely six months after listing, compounds selling pressure from the July 8 expiry of lock-up restrictions on the first batch of cornerstone investor shares, which account for approximately 4.3% of total issued capital. The dual impact of share dilution and expanded free float continues to weigh on the stock, which has retreated over 36% from its June 25 all-time high of HK$887.50.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)